Tag
Moderna
5 articles
Moderna Crushes Q3 Estimates, Narrows Spending Outlook
The biotech reported $1.31B in revenue and 38-cent EPS, both crushing consensus, while guiding FY capital spending to $200M and R&D to $2.7B.
Moderna at $225: Melanoma Data and NIH Backing Justify Bull Case
Moderna has surged 600 percent in 2026 on melanoma vaccine efficacy and reported NIH support for personalized cancer vaccines, with analysts modeling $225 as fair value.
Moderna Surges 177% on Melanoma Vaccine Win; Wall Street Raises Targets
Moderna stock soared on positive Phase 3 results for its personalized melanoma vaccine with Merck, prompting Morgan Stanley to raise its price target to $89 from $39.
Moderna Stock Drops 25% on Cancer Vaccine Success—Wall Street's Skepticism Shows Risk
Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.
Merck, Moderna's mRNA Melanoma Vaccine Succeeds in Phase 3 Trial
Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.